Ruxolitinib Active Not Recruiting Phase 1 Trials for Post Essential Thrombocythemia Myelofibrosis / Agnogenic Myeloid Metaplasia / Post Polycythemia Vera Myelofibrosis / Primary Myelofibrosis Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT03373877Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis
NCT01317875Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)